Clinical Trials
Below are current clinical trials.
269 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
This study aims to further understand the extent of long term effects of COVID-19 via batteries of self-assessment questionnaires focused on the most common complications of SARS-COVID 19 infections including respiratory and cardiovascular symptoms, frailty, fatigue, exercise capacity, cognitive and emotional functionality, and overall quality of life. Furthermore, we will investigate the impact of 4 weeks of respiratory muscle training and nasal breathing on the above mentioned long-term Covid-19 disease complications.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to assess the effectiveness and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
-
Rochester, Minn.
The purpose of this study is to evaluate the safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
-
Jacksonville, Fla.
The objectives of this study are to assess the ‘longer-term’ clinical, pulmonary, cardiac, functional, and psychosocial sequelae of COVID-19 survivorship, and to investigate whether exercise therapy enhances recovery of and/or improves pulmonary and cardiac function, exercise capacity, clinical status, and overall HRQoL in COVID-19 survivors.
-
Rochester, Minn.
The purpose of this study is to compare cardiopulmonary exercise testing with no filter to pre- and post-flow sensor placement.
-
Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The purpose of this study is assess the pharmacodynamics, pharmacokinetics, safety and effectiveness of two different doses of Tocilizumab (TCZ) in combination with Standard of Care (SOC) in hospitalized adult patients with moderate-to-severe COVID-19 pneumonia.
-
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care (SOC) can alleviate the immune-mediated cytokine release syndrome (CRS) and prevent progression to respiratory failure and/or death in high risk patients with COVID-19 pneumonia.
-
Rochester, Minn.
It is unclear if and how COVID19 can be passed from mother to child. Therefore, we aim to collect maternal and fetal samples from COVID19-infected pregnant women and compare them to pregnant women who have clinical indications for COVID 19 testing at the time of hospital admission but end up being COVID19- (control group). Pregnant women who are either COVID19+ or COVID19- with symptoms will be followed during this study. Our objective is to understand the prevalence of maternal fetal transmission, risk factors and outcomes of a COVID19+ pregnancy, and how the virus can be passed from mother to baby in the population of Mayo Clinic patients.
-
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness of inhaled molgramostim, administered open-label, to adult cystic fibrosis subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.
-
Rochester, Minn.
The specific aims of the study are to:
Aim 1. To determine the feasibility of a community-engaged research partnership to support rapid SARS-CoV-2 testing for symptomatic patients of all ages in the underserved population during the COVID-19 crisis. We will pilot a rapid testing strategy at OCHC using Mayo Clinic Laboratory (MCL) diagnostic processing.
Aim 2. Compare the effectiveness of community-driven messaging in increasing uptake of rapid SARS-CoV-2 testing compared with usual sources of health information. We will draw a simple random sample of OCHC patients (N=1000, age 18+) with 1:1 randomization of communication about COVID-19 and availability of rapid testing from OCHC versus usual sources (control).